Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA/SUFU guideline amendment

Journal of Urology

Volumn 193, Issue 5, 2015, Pages 1572-1580

  Gormley, E Ann ^a   Lightner, Deborah J ^a   Faraday, Martha ^a   Vasavada, Sandip Prasan ^a  

^a American Urological Association   (United States)

Author keywords

nocturia; urinary bladder; urinary incontinence

Indexed keywords

BOTULINUM TOXIN A; MIRABEGRON;

ADULT DISEASE; ARTICLE; BEHAVIOR THERAPY; CLINICAL PRACTICE; HUMAN; META ANALYSIS; NERVE STIMULATION; NON NEUROGENIC OVERACTIVE BLADDER; OVERACTIVE BLADDER; PATIENT COUNSELING; PERIPHERAL TIBIAL NERVE STIMULATION; PRACTICE GUIDELINE; PRIORITY JOURNAL; SACRAL NERVE STIMULATION; SYSTEMATIC REVIEW; ALGORITHM; FEMALE; MALE; URINARY BLADDER, OVERACTIVE;

ALGORITHMS; FEMALE; HUMANS; MALE; URINARY BLADDER, OVERACTIVE;

EID: 84927909261     PISSN: 00225347     EISSN: 15273792     Source Type: Journal    
DOI: 10.1016/j.juro.2015.01.087     Document Type: Article

References (33)

1. Hartmann KE, McPheeters ML, Biller DH, et al. Treatment of overactive bladder in women. Evidence Report/Technology Assessment Number 187 (Prepared by the Vanderbilt Evidence-based Practice Center under Contract No. 290-2007-10065-I). Rockville, MD: Agency for Healthcare Research and Quality (AHRQ) 2009.
2. B.T. Haylen, D. de Ridder, and R.M. Freeman An International Urogynecological Association (IUGA)/International Continence Society (ICS) joint report on the terminology for female pelvic floor dysfunction Neurourol Urodyn 29 2010 4
3. P. Abrams, L. Cardozo, and M. Fall The standardization of terminology of lower urinary tract function: report from the Standardisation Sub-Committee of the International Continence Society Neurourol Urodyn 21 2002 167
4. S. Kaya, T. Akbayrak, and S. Beksac Comparison of different treatment protocols in the treatment of idiopathic detrusor overactivity: a randomized controlled trial Clin Rehabil 25 2011 327
5. C. Song, J.T. Park, and K.O. Heo Effects of bladder training and/or tolterodine in female patients with overactive bladder syndrome: a prospective, randomized study J Korean Med Sci 21 2006 1060
6. A. Mattiasson, J. Blaakaer, and K. Hoye Simplified bladder training augments the effectiveness of tolterodine in patients with an overactive bladder BJU Int 91 2003 54
7. A. Mattiasson, A. Masala, and R. Morton Efficacy of simplified bladder training in patients with overactive bladder receiving a solifenacin flexible-dose regimen: results from a randomized study BJU Int 2009 E-pub ahead of print
8. K.L. Burgio, S.R. Kraus, and S. Menefee Behavioral therapy to enable women with urge incontinence to discontinue drug treatment: a randomized trial Ann Intern Med 149 2008 161
9. V. Khullar, G. Amarenco, and J.C. Angulo Efficacy and tolerability of mirabegron, a beta(3)-adrenoceptor agonist, in patients with overactive bladder: results from a randomised European-Australian phase 3 trial Eur Urol 63 2013 2
10. V.W. Nitti, S. Auerbach, and N. Martin Results of a randomized phase III trial of mirabegron in patients with overactive bladder J Urol 189 2013 4
11. S. Herschorn, J. Barkin, and D. Castro-Diaz A phase III, randomized, double-blind, parallel-group, placebo-controlled, multicentre study to assess the efficacy and safety of the beta(3) adrenoceptor agonist, mirabegron, in patients with symptoms of overactive bladder Urology 82 2013 2
12. C.R. Chapple, S.A. Kaplan, and D. Mitcheson Randomized double-blind, active-controlled phase 3 study to assess 12-month safety and efficacy of mirabegron, a beta(3)-adrenoceptor agonist, in overactive bladder Eur Urol 63 2013 2
13. O. Yamaguchi, E. Marui, and H. Kakizaki A phase III, randomized, double-blind, placebo-controlled study of the beta -adrenoceptor agonist, mirabegron 50 mg once-daily, in Japanese patients with overactive bladder BJU Int 113 2014 951
14. C.R. Chapple, V. Dvorak, and P. Radziszewski A phase II dose ranging study of mirabegron in patients with overactive bladder Int Urogynecol J 24 2013 9
15. C.R. Chapple, G. Amarenco, and M.A. Lopez Aramburu A proof-of-concept study: mirabegron, a new therapy for overactive bladder Neurourol Urodyn 32 2013 8
16. S.A. Sternberg, A.W. Schwartz, and S. Karunananthan The identification of frailty: a systematic literature review JAGS 59 2011 2129
17. C. Chapple, K.D. Sievert, and S. MacDiarmid OnabotulinumtoxinA 100 U significantly improves all idiopathic overactive bladder symptoms and quality of life in patients with overactive bladder and urinary incontinence: a randomised, double-blind, placebo controlled trial Eur Urol 64 2013 2
18. P. Denys, L. Le Normand, and I. Ghout Efficacy and safety of low doses of onabotulinumtoxinA for the treatment of refractory idiopathic overactive bladder: a multicentre, double-blind, randomised, placebo controlled dose-ranging study Eur Urol 61 2012 3
19. C. Jabs, and E. Carleton Efficacy of botulinum toxin A intradetrusor injections for non- neurogenic urinary urge incontinence: a randomized double-blind controlled trial J Obstet Gynaecol Can 35 2013 1
20. D.G. Tincello, S. Kenyon, and K.R. Abrams Botulinum toxin a versus placebo for refractory detrusor overactivity in women: a randomised blinded placebo-controlled trial of 240 women (the RELAX study) Eur Urol 62 2012 3
21. W. Altaweel, A. Mokhtar, and D.M. Rabah Prospective randomized trial of 100u vs 200u botox in the treatment of idiopathic overactive bladder Urology Ann 2 2011 66
22. C.J. Fowler, S. Auerbach, and D. Ginsberg OnabotulinumtoxinA improves health-related quality of life in patients with urinary incontinence due to idiopathic overactive bladder: a 36-week, double-blind, placebo-controlled, randomized, dose-ranging trial Eur Urol 62 2012 1
23. R. Dmochowski, C. Chapple, and V. Nitti Efficacy and safety of onabotulinumtoxinA for idiopathic overactive bladder: a double-blind, placebo controlled, randomized, dose ranging trial J Urol 184 2010 2416
24. L. Brubaker, H.E. Richter, and A. Visco Refractory idiopathic urge urinary incontinence and botulinum A injection J Urol 180 2008 217
25. H.C. Kuo Clinical effects of suburothelial injection of botulinum A toxin on patients with nonneurogenic detrusor overactivity refractory to anticholinergics Urology 66 2005 94
26. R.M. Bauer, C. Gratzke, and A. Roosen Patient-reported side effects of intradetrusor botulinum toxin type A for idiopathic overactive bladder syndrome Urol Int 86 2011 68
27. E. Finazzi-Agro, F. Petta, and F. Sciobica Percutaneous tibial nerve stimulation effects on detrusor overactivity incontinence are not due to a placebo effect: a randomized, double-blind, placebo controlled trial J Urol 184 2010 5
28. S.C. Souto, L.O. Reis, and T. Palma Prospective and randomized comparison of electrical stimulation of the posterior tibial nerve versus oxybutynin versus their combination for treatment of women with overactive bladder syndrome World J Urol 32 2013 1
29. K.M. Peters, D.J. Carrico, and S.A. MacDiarmid Sustained therapeutic effects of percutaneous tibial nerve stimulation: 24-month results of the STEP study Neurourol Urodyn 32 2013 1
30. K.M. Peters, D.J. Carrico, and L.S. Wooldridge Percutaneous tibial nerve stimulation for the long-term treatment of overactive bladder: 3-year results of the STEP study J Urol 189 2013 6
31. W. Yoong, P. Shah, and R. Dadswell Sustained effectiveness of percutaneous tibial nerve stimulation for overactive bladder syndrome: 2-year follow-up of positive responders Int Urogynecol J 24 2013 5
32. S. Siegel, K. Noblett, and J. Mangel Results of a prospective, randomized, multicenter study evaluating sacral neuromodulation with InterStim therapy compared to standard medical therapy at 6-months in subjects with mild symptoms of overactive bladder Neurourol Urodyn 2014 Epub ahead of print
33. K.M. Peters, L. Shen, and M. McGuire Effect of sacral neuromodulation rate on overactive bladder symptoms: a randomized crossover feasibility study LUTS Lower Urinary Tract Symptoms 5 2013 129